Sergio Gor, the US Ambassador to India and a close political ally of President Donald Trump, stood before an audience at IIT-Delhi on Friday and made a claim that would have seemed implausible twelve months ago: the long-sought trade agreement between the United States and India is, in his words, "99% done," with a signing expected within the coming weeks following a fresh round of negotiations in New Delhi.

The declaration carries weight precisely because of who is delivering it. Gor is not a career diplomat reading from a prepared brief — he is a Trump insider, the kind of envoy dispatched to deliver political results, not manage pleasant bilateral atmospherics. When he tells a room full of IIT engineers that a deal is imminent, it reflects a genuine push from the White House, not a State Department holding statement.

The timing matters too. The broader Trump trade strategy has put virtually every major US partner on notice, and India — long regarded as one of the most resistant negotiators on tariffs and market access — has signaled a new willingness to move. Washington has watched New Delhi reduce friction on several fronts, and the administration has reciprocated by framing India as what Gor called a "trusted pillar" in US supply chains across pharmaceuticals, semiconductors, and technology — a designation with real strategic consequences in a post-China-decoupling world.

Gor went further than trade in his IIT remarks. He called for deepening collaboration in artificial intelligence and pharmaceuticals specifically, invoking what he described as a "Pax Silica" framework — a vision of Indo-American technological interdependence that would lock the two countries into a shared industrial future. The phrase is deliberate. It positions the trade deal not as a transactional tariff negotiation but as the foundation of a civilizational-scale alignment. That is either a bold strategic vision or a very sophisticated sales pitch, possibly both.

Still, that remaining 1% deserves scrutiny. In trade negotiations of this complexity, the final fraction is almost never administrative. The unresolved issues in India-US talks have historically included agricultural market access — a politically radioactive subject in India — US demands around data localization and digital trade, and Indian insistence on protections for its generic pharmaceutical export sector, which supplies a significant share of the world's low-cost medicines and is fiercely guarded by New Delhi. Any one of these can detonate a near-final agreement. The graveyard of "almost done" US trade deals is well-populated.

The US State Department, for its part, has signaled that closing the India deal is a genuine priority — not a courtesy gesture. The accelerated meeting schedule between delegations suggests real momentum rather than the performative summitry that often substitutes for it. But momentum and a signed text are different things, and the administration has a demonstrated tendency to announce deals that subsequently slip.

What is confirmed: Gor made the remarks, the percentage claim is on the record, a US delegation has been in New Delhi for further talks, and both governments have publicly described the deal as a priority. What is not confirmed: the specific contours of what the "99%" actually covers, what sits inside that remaining 1%, and whether the weeks-away timeline survives contact with either country's domestic political pressures.

For India, the strategic calculus is unusually clear right now. A formal trade framework with Washington — even an interim one — insulates New Delhi from the tariff volatility that has rattled other US partners and cements its positioning as the preferred alternative to Chinese manufacturing in American supply chains. That is worth concessions that would have been politically unthinkable five years ago. Whether Modi's government has actually made those concessions, or whether both sides are counting the same chapter as closed, is the question a signed document will eventually answer.